EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real‐World Study in Patients With Nonvalvular Atrial Fibrillation

Gregory Y H Lip iD, Dong Cheng, Jenny Jiang iD, Chuan Gao, Rupesh Subash iD, Elisabeth Vodicka iD, Anandkumar Dubey, Puza P Sharma iD, Anakha Vettumthara Unnikrishnan, Kishorekumar Mathivanan, Steven Deitelzweig

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.044113 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Gregory Y H Lip und 10 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpoo…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Drug Substitution, Factor Xa Inhibitors, Hemorrhage. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real‐world research has identified differences in effectiveness and safety between direct oral anticoagulants (DOACs) when used to reduce risks of stroke and systemic embolism in patients with atrial fibrillation. However, treatment decisions and subsequent outcomes are poorly understood in patients with atrial fibrillation who experience bleeding when receiving a DOAC.

Methods

A retrospective observational study was conducted using US claims data from Optum’s Clinformatics Data Mart Database (January 2012 through March 2024). The study population comprised adults with nonvalvular atrial fibrillation who initiated a DOAC and had a subsequent claim for bleeding. After propensity score matching, patients who persisted with the same DOAC after bleeding were compared with those who switched to another DOAC. The main outcomes were major bleeding and stroke/systemic embolism.

Results

Among 59 620 apixaban initiators and 21 004 rivaroxaban initiators with bleeding while on therapy, 408 apixaban‐to‐rivaroxaban switchers were matched with 2040 persistent apixaban users, and 901 rivaroxaban‐to‐apixaban switchers were matched with 4505 persistent rivaroxaban users. Compared with persisting with apixaban following a bleeding event, apixaban‐to‐rivaroxaban switching was associated with a higher risk of major bleeding (hazard ratio [HR], 1.690 [95% CI, 1.130–2.527]) and a similar risk of stroke/systemic embolism (HR, 1.793 [95% CI, 0.765–4.202]). Compared with persisting with rivaroxaban, rivaroxaban‐to‐apixaban switching was associated with a lower risk of major bleeding (HR, 0.651 [95% CI, 0.460–0.920]) and a similar risk of stroke/systemic embolism (HR, 0.783 [95% CI, 0.371–1.652]).

Conclusions

These findings suggest that the choice of DOAC after a bleeding event can affect treatment outcomes in patients with atrial fibrillation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDrug SubstitutionFactor Xa InhibitorsHemorrhagePyrazolesPyridonesRivaroxabanAgedAged, 80 and overFemaleHumansMaleMiddle AgedEmbolismRetrospective StudiesRisk FactorsStrokeTreatment OutcomeUnited States

Stichwörter der Autor:innen

atrial fibrillationdirect oral anticoagulanthemorrhagestrokeswitching

Substanzen

apixabanFactor Xa InhibitorsPyrazolesPyridonesRivaroxaban

Autor:innen und Institutionen

  • Liverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpool United Kingdom.
  • Danish Center for Health Services Research, Department of Clinical Medicine Aalborg University Aalborg Denmark.
  • Department of Cardiology, Lipidology and Internal Medicine with Intensive Coronary Care Unit Medical University of Bialystok Bialystok Poland.
  • Bristol Myers Squibb Company Lawrenceville NJ USA.
  • Pfizer Ltd. Tadworth United Kingdom.
  • Pfizer Inc. New York NY USA.

ORCID-Profile: Gregory Y H Lip, Jenny Jiang, Rupesh Subash, Elisabeth Vodicka, Puza P Sharma

Zitieren

APA

Lip, G. Y. H., Cheng, D., Jiang, J., Gao, C., Subash, R., Vodicka, E., Dubey, A., Sharma, P. P., Vettumthara Unnikrishnan, A., Mathivanan, K., & Deitelzweig, S. (2026). Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real‐World Study in Patients With Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.044113

Vancouver

Lip GYH, Cheng D, Jiang J, Gao C, Subash R, Vodicka E, et al. Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real‐World Study in Patients With Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.044113

BibTeX
@article{Lip2026,
  author = {Lip, Gregory Y H and Cheng, Dong and Jiang, Jenny and Gao, Chuan and Subash, Rupesh and Vodicka, Elisabeth and Dubey, Anandkumar and Sharma, Puza P and Vettumthara Unnikrishnan, Anakha and Mathivanan, Kishorekumar and Deitelzweig, Steven},
  title = {Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real‐World Study in Patients With Nonvalvular Atrial Fibrillation},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.044113}
}
Kostenlos starten →